Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:GLUE

Monte Rosa Therapeutics Q3 2026 Earnings Date & Estimates

Monte Rosa Therapeutics logo
$10.30 -0.02 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$10.38 +0.08 (+0.78%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Monte Rosa Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Monte Rosa Therapeutics in Q3 2026

Monte Rosa Therapeutics is expected to post earnings of -$0.2396 per share on revenue of $31.48 million. In the same quarter a year earlier Monte Rosa Therapeutics reported -$0.33 per share on revenue of $12.77 million. Monte Rosa Therapeutics last reported on August 6, 2026, posting -$0.43 per share and missing the -$0.3805 consensus estimate. Monte Rosa Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.2396
Expected Revenue
$31.48 million
Prior-Year EPS
-$0.33
Prior-Year Revenue
$12.77 million
Expected Revenue Growth
+146.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.43 (Missed by -$0.0495)
Last Quarter Revenue
$8.97 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Monte Rosa Therapeutics Q3 2026 Earnings FAQ

Monte Rosa Therapeutics (NASDAQ:GLUE) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Monte Rosa Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Monte Rosa Therapeutics to post earnings of -$0.2396 per share for Q3 2026.

The consensus revenue estimate for Monte Rosa Therapeutics is $31.48 million for Q3 2026.

Monte Rosa Therapeutics Earnings Headlines

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952091-monte-rosa-therapeutics-inc-glue-discusses-gforceminus-1-phase-i-results-for-nek7-molecular
Head-To-Head Survey: GeoVax Labs (NASDAQ:GOVX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085173
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
October 9 at 1:00 AM  |  Altimetry (Ad)
Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)
October 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GLUE/pressreleases/4942414/piper-sandler-remains-a-buy-on-monte-rosa-therapeutics-glue/
Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded at HC Wainwright
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083719
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Falls 6% - What's Next?
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082945
See More Monte Rosa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics (NASDAQ:GLUE) is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary molecular glue degrader platform to identify small molecules that recruit targeted proteins to the cell’s natural protein-disposal machinery, potentially addressing proteins that have been difficult to treat with conventional drugs.

Monte Rosa’s pipeline is centered primarily on autoimmune and inflammatory diseases, as well as other serious conditions. Its lead programs include MRT-6160, an oral molecular glue degrader designed to target VAV1, a protein involved in immune-cell signaling, and additional discovery and development programs aimed at other disease-relevant targets. The company’s platform is intended to support the development of medicines across multiple therapeutic areas.

Founded in 2018 and headquartered in Boston, Massachusetts, Monte Rosa conducts research and clinical development with the goal of serving patients globally. The company became a publicly traded company in 2021 and is led by a team of biotechnology and drug-development professionals.

View Monte Rosa Therapeutics Profile
Earnings Tools